Big Flats, NY – (April 28, 2008) - X-GEN Pharmaceuticals Inc announces that it has entered into an exclusive distribution agreement with Eurand Pharmaceuticals Inc. for the company's non-branded pancreatic enzyme product (PEP) Pancrelipase. In accordance with the agreement, X-GEN will represent Eurand as its authorized exclusive distribution agent for its currently marketed unbranded product. Consistent with the April 28, 2004 Federal Register Notification (as supplemented in October 2007), Eurand has both an IND and an NDA on file for a pancreatic enzyme product and is actively seeking regulatory approval. As Eurand's exclusive distribution agent, X-GEN will supply the product in four separate strengths. Pancrelipase 4,500 (NDC# 39822-9045-1), Pancrelipase 10,000 (NDC# 39822-9100-1), Pancrelipase 16,000 (NDC# 39822-9160-1) and Pancrelipase 20,000 (NDC# 39822-9200-1) Capsules are orally administered and contain delayed-release microspheres of porcine pancreatic enzyme concentrate, predominantly pancreatic lipase, amylase and protease. For further information about these pancreatic enzyme products, contact X-GEN Pharmaceuticals at (607) 562-2700.

X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN’s expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, powders for prescription compounding and inhalants. For further information about X-GEN Pharmaceuticals call (866) 390-4411, or visit the web-site at www.x-gen.us.

Big Flats, NY - March 2008 --- X-GEN Pharmaceuticals Inc. announced it recently earned MedAssets Supply Chain Systems' Gold Vendor status. The Gold level is the highest vendor designation awarded by MedAssets Supply Chain Systems, a MedAssets company. 98 vendors were awarded the Gold Vendor designation at the MedAssets Healthcare Business Summit in Las Vegas in March 2008, attended by more than 3,000 healthcare professionals. The award recognizes outstanding vendors and is based on improving customer savings and customer satisfaction, filing reports and submitting fee schedules in a timely manner, continuous growth in purchase volume, and supporting MedAssets' philanthropic efforts.

About X-GEN


X-GEN Pharmaceuticals Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN's expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, powders for prescription compounding and inhalants. For further information about X-GEN Pharmaceuticals call (866) 390-4411, or visit the web-site at www.x-gen.us

About MedAssets

MedAssets (NASDAQ: MDAS) partners with healthcare providers to improve their financial strength by implementing integrated spend management and revenue cycle solutions that help control cost, improve margins and cash flow, increase regulatory compliance, and optimize operational efficiency. MedAssets serves more than 125 health systems, 2,500 hospitals and 30,000 non-acute care healthcare providers. For more information, visit www.medassets.com.

For further information contact:
X-GEN Pharmaceuticals, Inc.
Tel: 607-562-2700
www.x-gen.us.

Big Flats, NY – December 17, 2007 - X-GEN Pharmaceuticals announced that it will begin marketing Fomepizole Injection on December 14, 2007.^[1]Fomepizole Injection is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected cases of ethylene glycol or methanol ingestion. Fomepizole Injection is AP rated and equivalent to Antizol® by Jazz Pharmaceuticals. This product is the first generic Fomepizole Injection approved by the U.S. Food and Drug Administration. Fomepizole Injection is supplied as a sterile, preservative-free solution. It is packaged in single vial cartons. Each vial contains 1.5mL (1g/mL) of Fomepizole (NDC# 39822-0710-1). The product should be stored at 20° - 25° C (68° - 77° F) [See USP Controlled Room Temperature]. X-GEN President and CEO Susan Badia points out that the introduction of Fomepizole Injection is another demonstration of X-GEN’s commitment to supporting affordable patient care. “Adding the first generic alternative to Antizol® reflects our commitment to providing generic pharmaceutical products which enhance patient care as cost-effective alternatives to their respective branded counterparts. We look forward to serving the healthcare community as the preferred source for Fomepizole Injection.” ^[1] Refer to full prescribing information for precautions

About X-GEN

X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN’s expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, powders for prescription compounding and inhalants. For further information about X-GEN Pharmaceuticals call (866) 390-4411, or visit the web-site at www.x-gen.us.